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Background: There is evidence that obesity could be a risk factor for the severity and 
response to treatment in adult patients with rheumatoid arthritis (RA) due both to the 
mechanical effect of overweight and to the potential pro-inflammatory effects of cytokines 
produced by adipose tissue.
Objectives: To evaluate the role of overweight and obesity in a cohort of young patients 
with juvenile idiopathic arthritis (JIA) in terms of incidence, disease activity, outcome, and 
response to treatments.
Methods: This single-center retrospective cohort study evaluated 110 children affected by 
JIA under treatment with conventional disease-modifying antirheumatic drugs (DMARDs) 
and biologic agents. Body mass index (BMI) categories of 5–84th (normal weight), 85–94th 
(overweight), and ≥95th (obese) percentile were used. Patients with systemic JIA, uveitis, 
chronic comorbidities, or under other potentially confounding systemic treatments were 
excluded. Uni- and multivariate analyses were performed.
Results: One hundred and ten JIA patients (polyarticular n = 50, oligoarticular n = 38, 
psoriatic n = 12, enthesitis-related arthritis n = 8, undifferentiated n = 2) were enrolled in 
the study, 75% girls and 25% boys. The mean age at treatment onset was 6.09 years. 
Baseline BMI was ≥5th and ≤84th percentile in 80 patients, 85–94th in 27, and ≥95th in 3. 
We did not observe a significant association between BMI and erythrocyte sedimentation 
rate (ESR), C-reactive protein (CRP), or number of active joints at baseline, while 
involvement of the joints of lower limbs was significantly greater ( p = 0.025) in overweight/
obese patients. However, a trend toward lower remission rates and higher number of 
relapses, both after DMARDs and biologics, in patients with higher BMI was observed.
Conclusion: This study focuses on the relationship between overweight/obesity and JIA. 
A significant correlation between obesity and a greater involvement of the joints of the 
lower limbs at baseline was demonstrated. Furthermore, our data suggest that obesity 
could negatively influence the course of the disease as well as treatment response.
Keywords: obesity, overweight, body mass index, juvenile idiopathic arthritis, disease-modifying antirheumatic 
drugs, biologics
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INTRODUCTION
Obesity is a medical condition characterized by an excess in body 
fat accumulation associated with a potentially negative impact 
on health (Fact Sheet on Obesity and Overweight, 2006). Body 
mass index (BMI, weight/height2, kg/m2) is the most widely used 
method to define obesity and overweight, although it does not take 
into account body composition and the share of adiposity (Cole 
et al., 2000). Referring to the US Centers for Disease Control and 
Prevention (CDC) BMI-for-age growth chart, obesity is defined 
among subjects aged 2 to 19 years in the presence of a BMI at 
or above the sex-specific 95th percentile, while overweight is 
defined as a BMI at or above the 85th percentile and below the 
95th (Krebs et al., 2007; Katzmarzyk et al., 2015).
The prevalence of overweight and obesity in European countries 
accounts for 53.1%, and in the pediatric age, it is about 20%, 
ranging from 40% in Southern Europe to less than 10% in Northern 
European countries (Ahrens et al., 2014; Marques et al., 2018).
An increased accumulation of body fat represents a significant 
risk factor for metabolic complications and a modifiable variable 
for a number of chronic diseases (Finucane et al., 2011). A wealth 
of studies both in mice and in humans have shown increased levels 
of pro-inflammatory cytokines in adipose tissues, including TNF-
α, interleukin 6 (IL-6), IL-1β, and several other inflammatory 
proteins (Hotamisligil et al., 1995; Berg and Scherer, 2005).
Recently, evidence has emerged in favor of the potential 
negative influence of obesity on rheumatoid arthritis (RA) 
disease progression, disease severity, and treatment response 
(Klaasen et al., 2011; Gremese et al., 2013; Heimans et al., 2013; 
Ellerby et al., 2014; Sandberg et al., 2014; Liu et al., 2017). Liu 
et al. (2017) in their meta-analysis documented the unfavorable 
effect of obesity on achieving remission in RA and its impact on 
disease activity and patient-reported outcomes during therapy. 
Conversely, only few data have been published about the effect of 
obesity on juvenile idiopathic arthritis (JIA).
Thus, the goal of our study was to investigate the relationship 
between BMI and JIA in terms of baseline disease activity and 
response to classic disease-modifying antirheumatic drugs 
(DMARDs) and biological agents.
MATERIALS AND METHODS
A retrospective study was conducted with an analysis of the 
medical records of children with JIA classified according to 
International League of Associations for Rheumatology (ILAR) 
criteria that were seen in the Pediatric Rheumatology Unit 
of Anna Meyer Children Hospital between January 2009 and 
January 2017 (Petty et al., 2004). Only patients who needed 
systemic drugs were selected. Arthritis related with uveitis and 
systemic JIA subtypes were considered exclusion criteria.
Demographic data, age at disease onset, anthropometric 
measurements, disease duration, laboratory data, joint involvement, 
and medications including DMARDs and biologic drugs were 
extracted from charts and inserted into a dedicated database. 
Patients were usually evaluated every 3 months with a thorough 
physical examination inclusive of assessment of the number and the 
type of active joints (swelling or both tenderness and limited range 
of motion) and laboratory investigations.
Height was measured with a wall-mounted stadiometer to 
the nearest 0.1 cm, while for weight, a calibrated beam balance 
platform scale to the nearest 0.1 kg was used. BMI was calculated 
as weight in kilograms divided by height in square meters. BMI-
for-age percentiles were computed using the CDC reference 
values. Normal BMI was defined as the 5th percentile to less 
than the 85th percentile, overweight as the 85th to less than the 
95th percentile, and obese as equal to or greater than the 95th 
percentile (Kuczmarski et al., 2002).
Relevant laboratory variables included erythrocyte sedimentation 
rate (ESR), and C-reactive protein (CRP). Clinically inactive disease 
status was defined as no joints with active disease, an ESR of 
≤20 mm/h, and CRP ≤0.5 mg/dl.
The data were analyzed using the person time method. Patients on 
treatment with first-line drugs (DMARDs) were followed from the 
start of treatment up to the date of remission or last follow-up. 
The remission rates for person-months were therefore calculated. 
The rates of relapse were calculated as the number of relapse (first 
occurrence) after remission on person-months at risk. The amount 
of person-months was the sum of months at risk from the date of 
remission to the date of relapse or of the last follow-up. For subjects 
eligible for treatment with biological drugs, remission and relapse 
post-remission rates were calculated using the same method. We 
performed univariate and multivariate analysis and included in the 
models clinically and statistically relevant variables as covariate. All 
analyses were performed with the STATA 11 software.
Since we used deidentified data, according to national 
regulation, no ethics committee approval or informed consent 
was needed.
RESULTS
Demographic and clinical data are reported in Table 1. One 
hundred and ten JIA patients (polyarticular n = 50, oligoarticular 
n = 38, psoriatic n = 12, enthesitis-related arthritis n = 8, 
undifferentiated n = 2) were enrolled in the study, 75% girls and 
25% boys. The mean age at conventional DMARDs treatment 
onset was 6.09 years. Baseline BMI was included between the 5th 
and 84th percentile in 80 patients, 85–94th in 27, and ≥95th in 3.
At baseline, ESR and CRP values were increased, although not 
significantly, in overweight/obese compared with healthy weighted 
individuals (p = 0.373 and 0.176 for ESR and CRP, respectively). 
The number of active lower limb joints was significantly lower (p = 
0.028) in healthy weighted than in overweight/obese individuals 
(Table 1).
Sixty-nine patients out of 110 achieved remission on conventional 
DMARDs. The remission rate was 93.88/1000 person-months, with 
higher remission rates in healthy weighted children (98.87) than in 
obese children (83.58). At univariate analysis, however, the difference 
did not reach statistical significance. The hazard ratio (HR) in 
obese children compared with healthy weighted children was 0.8, 
CI 95% 0.46–1.40. An abnormal CRP value was the only covariate 
influencing the remission rate, close to statistical significance (HR 
1.79, CI 95% 0.98–3.26) (Table 2).
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The multivariate analysis showed a significant effect of 
elevated CRP value on the remission rate (HR 2.21, CI 95% 
1.12–4.35). Lower remission rates were observed in children 
with an overweight/obese BMI and a higher number of active 
joints (more than five) at baseline as well as in patients with 
increased values of ESR and CRP compared to normal values 
(HR 1.77, CI 95% 0.62–5.06 and HR 1.72, CI 95% 0.75–3.98, 
for ESR and CRP, respectively), although without a statistical 
significance (Tables 3 and 4). Thirty-five patients out of 69 
relapsed after remission, with a relapse rate of 13.40/1000 
person-months. The relapse rate was slightly higher in obese 
TABLE 1 | Baseline characteristics of the population.
Variables BMI 5–84th percentile BMI ≥85th percentile Total p
Age (years) at enrollment Mean (SD) 6.0 (4.04) 6.2 (3.4) 6.0 (3.8) 0.7782
Age at puberty (years) Mean (SD) 11.4 (1.7) 10.5 (1.4) 11.1 (1.7) 0.1197
Gender Females 57 (71.2%) 26 (86.6%) 83 (75.4%) 0.094
Males 23 (28.7%) 4 (13.3%) 27 (24.5%)
ESR (mm/h) 0–19 23 (30.2%) 6 (21.4%) 29 (27.8%) 0.373
≥ 20 53 (69.7%) 22 (78.5%) 75 (72.1%)
CRP (mg/dl) 0.0–0.49 32 (43.2%) 8 (28.5%) 40 (39.2%) 0.176
≥ 0.5 42 (56.7%) 20 (71.4%) 62 (60.7%)
Number of active joints 0–4 49 (61.2%) 13 (43.3%) 62 (56.3%) 0.092
≥ 5 31 (38.7%) 17 (56.6%) 48 (43.6%)
Number of active joints in 
lower limbs 
0–4 66 (88%) 18 (69.2%) 84 (83.1%) 0.028*
≥ 5 9 (12%) 8 (30.7%) 17 (16.8%)
JIA category ERA 6 (7.5) 2 (6.6) 8 (7.2) 0.645
Undifferentiated 1 (1.2) 1 (3.3) 2 (1.8)
Oligoarticular 31 (38.7) 7 (23.3) 38 (34.5)
Polyarticular RF neg 33 (41.2) 16 (53.3) 49 (44.5)
Polyarticular RF pos 1 (1.2) 0 (0.0) 1 (0.9)
Psoriatic 8 (10.0) 4 (13.3) 12 (10.9)
*Statistical significance.
TABLE 2 | Remission with classical DMARDs.
Variables n events Person-months Incidence rate × 1000 
person-months
Hazard ratio 
(CI 95%)
All patients 69 734.9 93.8
BMI
5–84th percentile 48 485.4 98.8 1
≥85th percentile 17 203.4 83.5 0.8 (0.46–1.40)
Age at puberty (years)
0–10 9 103.2 87.2 1
≥11 13 171.7 75.7 0.74 (0.3–1.84)
ESR (mm/h)
0–19 15 154.2 97.2 1
≥20 50 498.8 100.2 1.23 (0.67–2.27)
CRP (mg/dL)
0.0–0.49 20 246.98 80.98 1
≥0.50 43 391.64 109.80 1.79 (0.98–3.26)
Number of active joints 
0–4 39 371.2 105.0 1
≥5 30 363.6 82.4 0.80 (0.48–1.31)
Number of active joints in lower 
limbs 
0–4 52 576.3 90.2 1
≥5 11 109.5 100.4 1.28 (0.65–2.5)
Incidence rate × 1,000 person-months and hazard ratio. Univariate analysis.
TABLE 3 | Remission with classic (DMARDs).
Variables Hazard ratio (CI 95%)
BMI (percentile) 0–84th 1
≥85th 0.77 0.42–1.43
CRP (mg/dL) 0.0–0.49 1
≥0.50 2.21 1.12–4.35
Number of active joints 0–4 1
≥5 0.67 0.37–1.20
Multivariate analysis. Cox regression.
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children (15.79) than in healthy weighted children (13.37). The 
HR was 1.25, CI 95% 0.6–2.6.
The Cox regression showed a higher HR of relapse rate 
in overweight/obese children compared to healthy weighted 
children, and in children with abnormal values of CRP compared 
to those with normal values. However, all HR estimates did not 
reach statistical significance (Table 5).
Forty-eight patients required a second-line treatment: 27 
etanercept (13 in overweight/obese), 19 adalimumab (5 in overweight/
obese), and 2 abatacept (all in healthy weighted children).
Remission rate with second-line therapy was 122.12/1,000 
person-months, higher in healthy weighted children (146.21) than 
in obese children (87.45). The HR was 0.61, CI 95% 0.31–1.20.
Remission rates were lower in individuals with several active 
joints when compared with those with few active joints (>4 vs. 
0–4). The corresponding HR were 0.59, CI 95% 0.32–1.08 for 
more than 4 active joints vs. 0–4, and 0.46, CI 95% 0.19–1.13 
(>4 vs. 0–4 joints) considering only lower limbs (Table 6). The 
multivariate analysis confirmed the results of the univariate 
calculation (Table 7).
DISCUSSION
We investigated the negative effect exerted by obesity on JIA 
as suggested by data on adults affected by RA. Although JIA 
shares some features with RA, they should be considered distinct 
diseases. JIA represents the most common rheumatic disease 
of childhood with a prevalence of 16–150 cases per 100,000 
children (Prakken et al., 2011). Regardless of the differences 
in the underlying pathogenesis of the various types of JIA, the 
immunopathology involves a predominant abnormality of the 
adaptive immune system with a consistent overproduction of 
pro-inflammatory cytokines, many of which, such as TNF-α, IL-1, 
and IL-6, have been shown to be increased also in the presence 
of adipose expansion.
We observed a very small number of obese subjects in our 
cohort of patients; therefore, we divided it into two groups, 
one comprising children with a “healthy weight” (BMI < 85th 
percentile) and the other comprising children with an “increased 
weight” (BMI ≥ 85th percentile). Overweight/obesity rate in our 
study population is 27%, reflecting the pediatric prevalence of 
this condition in our country. We also excluded patients affected 
by systemic subtype, for its clinical heterogeneity compared to 
the other JIA subtypes, and patients with uveitis, which may 
require further treatments despite a good arthritis control, to 
avoid confounding factors.
At baseline, we observed a negative influence of obesity/
overweight on disease activity. Our JIA overweight/obese children 
showed a tendency to have a greater number of active joints, in 
particular those of lower limbs, and higher values of ESR and CRP 
compared to healthy weight subjects.
Few data are available about the impact of obesity on JIA. A 
first study by Pelajo et al. analyzed 154 JIA subjects, 18% of whom 
were obese and 12% were overweight; no association was found 
TABLE 5 | Relapse post-remission with classic DMARDS.
Variables Hazard ratio (CI 95%)
BMI (percentile) 0–84th 1
≥85th 1.35 0.61–2.98
CRP (mg/dL) 0.0–0.49 1
≥0.50 1.90 0.80–4.48
Number of joints involved 0–4 1
≥5 0.73 0.34–1.57
Multivariate analysis. Cox regression.
TABLE 4 | Relapse post-remission with classic DMARDs.
Variables n events Person-months Incidence rate × 1000 
person-months
Hazard ratio (CI 95%)
All patients 35 2611.0 13.4
BMI
0–84th percentile 22 1645.0 13.3 1
≥85th percentile 11 696.8 15.7 1.25 (0.6–2.6)
Age at puberty (years)
0–10 8 268.7 29.7 1
≥11 9 538.8 16.7 0.58 (0.22–1.50)
ESR (mm/h)
0–19 4 515.7 7.7 1
≥20 29 1925.2 15.0 1.77 (0.62–5.06)
CRP (mg/dL)
0.0–0.49 7 799.01 8.76 1
≥0.50 26 1607.34 16.18 1.72 (0.75–3.98)
Number of active joints 
0–4 19 1407.9 13.5 1
≥5 16 1203.1 13.3 0.92 (0.47–1.82)
Number of active joints in 
lower limbs 
0–4 27 1910.8 14.1 1
≥5 5 500.3 9.9 0.68 (0.26–1.78)
Incidence rate × 1000 person-months and hazard ratio. Univariate analysis.
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between obesity and disease activity in terms of Juvenile Arthritis 
Disease Activity Score 27, physician’s assessment of  disease 
activity, parent’s assessment of child’s well-being, CRP, ESR, and 
number of active joints (Pelajo et al., 2012).
On the other hand, Amine et al. (2011) in their series of 58 
Moroccan JIA patients, characterized by high BMI prevalence 
(41.4% overweight and 22.4% obese), observed a correlation 
between overweight and functional limitation and severe joint pain.
In 2016, Makay et al. studied 72 patients with enthesitis-
related arthritis, 27% of whom have a BMI ≥ 85th percentile. In 
subjects with increased BMI, they observed a higher frequency 
of tarsitis and ankle arthritis at baseline, while sacroiliac, hip, and 
entheses involvement as well as ESR values were similar to those 
with a BMI < 85th percentile (Makay et al., 2016).
Compared to adult RA, the correlation between disease 
activity and obesity seems to be less evident in JIA. Furthermore, 
data regarding the influence of BMI in treatment responses and 
outcome are still very poor in the pediatric age. In RA, obesity 
appears to be a strong predictor of worse treatment responses, 
decreasing the chances of achieving good disease control during 
the early phase, in which most of the patients receive DMARDs 
(Sandberg et al., 2014). Some recent studies have shown that the 
effect of TNF blockage also appears to be impaired in obese RA 
patients, while no significant difference between obese and non-
obese were seen in patients treated with abatacept and tocilizumab 
(Klaasen et al., 2011; Gremese et al., 2013; Iannone et al., 2015; 
Kim et al., 2016; Shan and Zhang, 2018). The modification in the 
pharmacokinetics and pharmacodynamics of drugs related to the 
excess of fat has been hypothesized to influence the response to 
therapy. On the other hand, obesity may mask early identification 
of active joints, delaying the beginning of the correct treatment 
(Barnabe et al., 2014).
In pediatrics, only the study by Makay et al. (2016) evaluated 
the response to therapy in patients with enthesitis-related 
arthritis with different BMI, reporting a failure in achieving a 
clinically inactive disease in children with a higher BMI treated 
with DMARDs or anti-TNF drugs, suggesting a negative effect of 
obesity on disease outcome.
In our JIA population, obesity/overweight corresponds to 
a worse trend in the therapeutic response both to first-line 
treatments and to anti-TNF drugs, although without reaching 
statistical significance.
Despite the fact that our data do not identify obesity as an 
independent risk factor for JIA, they suggest a negative influence 
on disease activity at baseline and an unfavorable impact on the 
therapeutic response to conventional DMADs and anti-TNF 
drugs. These observations may take into consideration weight 
management with dietary and physical activity interventions as 
part of the treatment strategy for obese/overweight patients.
Limitations of our study include the fact that few of our 
patients were obese and that the sample size of our population 
was relatively small; this may have hampered the achievement of 
statistical significance of several comparisons. Nonetheless, our 
study is one of the few that have investigated such factors and 
deserves further investigations.
TABLE 6 | Remission with second-line therapy (biologics).
Variables n events Person-months Incidence rate × 1000 
person-months
Hazard ratio (CI 95%)
All patients 43 352.1 122.1
BMI
0–84th percentile 27 184.6 146.2 1
≥85th percentile 14 160.1 87.4 0.61 (0.31–1.20)
Age at puberty (years)
0–10 10 114.1 87.5 1
≥11 13 91.3 142.2 1.56 (0.66–3.68)
ESR (mm/h)
0–19 13 96.3 134.9 1
≥20 22 216.5 101.6 0.81 (0.40–1.63)
CRP (mg/dl)
0.0–0.49 20 155.93 128.26 1
≥0.50 15 155.04 96.75 0.76 (0.38–1.51)
Number of active joints 
0–4 20 119.3 167.5 1
≥5 23 232.7 98.8 0.59 (0.32–1.08)
Number of active joints in 
lower limbs
0–4 31 200.0 154.9 1
≥5 6 67.9 88.3 0.46 (0.19–1.13)
Incidence rate × 1000 person-months and hazard ratio. Univariate analysis.
TABLE 7 | Remission with second-line therapy (biologics).
Variables Hazard ratio (CI 95%)
BMI (percentile) 0–84th 1.0
≥85th 0.49 (0.19–1.24)
Age at puberty (years) 0-10 1.0
≥11 1.93 (0.77–4.80)
Number of active joints 0–4 1.0
≥5 0.49 (0.20–1.20)
Multivariate analysis. Cox regression.
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